<DOC>
	<DOCNO>NCT02496520</DOCNO>
	<brief_summary>Phase I/II , open , prospective clinical trial , historically control . The objective evaluate safety , secondary measure , efficacy experimental treatment base cellular therapy ( vaccination autologous dendritic cell pulse tumor lysate ) patient affect metastatic relapse sarcoma ( Central Nervous System ) CNS tumor .</brief_summary>
	<brief_title>Dendritic Cell-based Immunotherapy Advanced Solid Tumours Children Young Adults</brief_title>
	<detailed_description>Phase I/II , open , prospective clinical trial , historically control . Patients affect metastatic relapse sarcoma ( Central Nervous System ) CNS tumor include . The patient receive standard treatment experimental treatment base cellular therapy vaccination autologous dendritic cell pulse tumor lysate . The immunization schedule include 4 monthly vaccine , 4 bimonthly quarterly remain vaccine . The vaccine administer intradermally combination standard treatment type tumor .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>Signed informed consent Diagnosis metastatic relapse sarcoma high grade central nervous system tumor From 3 40 year Surgery feasibility . In central nervous system tumor , residual tumor surgery must minimal . Toxicity liver , medullar , renal insufficiency advise participation Pregnant breast feed woman Diagnosis tumor basal cell squamous carcinoma skin situ cervix carcinoma Immunosuppressive treatment Human Immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C syphilis infection</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>dendritic cell vaccination</keyword>
	<keyword>sarcoma</keyword>
	<keyword>central nervous system tumor</keyword>
	<keyword>childhood</keyword>
	<keyword>adolescent</keyword>
	<keyword>immunotherapy</keyword>
</DOC>